New results show Eli Lilly Ebglyss (lebrikizumab-lbkz) improved skin (including hand and face) and itch among patients with ...

The boom experienced by the weight loss drug market comes as little surprise when considering that almost a third of the ...

The 62-year-old administrative law judge has Type 1 diabetes and needs the medication to live. The pharmacist ...

After seven months of living and working onboard the International Space Station (ISS), astronauts of NASA's eighth ...

DTIL is expected to provide updates on its in vivo gene editing programs in the third-quarter earnings release, given the ...

Pfizer CEO Albert Bourla is in a tough spot as activist investor Starboard Value continues to call for a change in the ...

As the demand for weight loss injectables soars, so too does the market for off-brand alternatives, some of which may not be ...

HCA stock dived after the hospital operator missed Q3 estimates, blaming hurricanes for the miss and muted outlook. Here's what else may worry investors.

Citi raised the firm’s price target on Eli Lilly (LLY) to $1,250 from $1,060 and keeps a Buy rating on the shares following a transfer of ...

New results show Eli Lilly’s Ebglyss improved skin and itch among patients with moderate-to-severe atopic dermatitis who were previously treated with dupilumab. These results fr ...

The company is suing some online vendors and medical spas for selling copycats of a weight loss and diabetes drug.

ResMed beat Wall Street estimates for quarterly profit on Thursday, driven by strong demand for its devices used for sleep ...